Pentoxifylline - CAS 6493-05-6
Catalog number: 6493-05-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Phosphodiesterase (PDE)
Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis, and reduces inflammation and innate immunity. It improves red blood cell deformability, reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation. It also reduces AST and ALT levels and may improve liver histological scores in patients with NALFD/NASH, but did not appear to affect cytokines.
Trental; PTX; Oxpentifylline
Canonical SMILES:
1.Microemulsion for topical application of pentoxifylline: In vitro release and in vivo evaluation.
Cavalcanti AL1, Reis MY1, Silva GC2, Ramalho ÍM2, Guimarães GP2, Silva JA1, Saraiva KL3, Damasceno BP4. Int J Pharm. 2016 Apr 27;506(1-2):351-360. doi: 10.1016/j.ijpharm.2016.04.065. [Epub ahead of print]
Microemulsion containing pentoxifylline was developed and characterized for use as a topical alternative to treat skin disorders. The transparent formulation was developed and optimized based on a pseudoternary phase diagram. Pentoxifylline-loaded microemulsion (PTX-ME) was composed of 44% Tween 80™/Brij 52™ mix as surfactants (S), 51% of caprylic/capric triglycerides as the oil phase (O) and 5% of water as aqueous phase (A). It was classified as an isotropic water-in-oil (W/O) system with droplets that had a heterogeneous spherical shape within the nanosized range (67.36±8.90nm) confirmed by polarized light microscopy, differential scanning calorimetry (DSC), transmission electron microscopy (TEM) and dynamic light scattering (DLS) analysis. In vitro studies using static diffusion Franz cells revealed that the release of PTX from ME followed the Higuchi kinetic model. Topical PTX-ME application developed superior anti-inflammatory activity when compared to the PTX solution, reducing the paw edema up to 88.
2.Pentoxifylline treatment in patients with cancer cachexia: A double-blind, randomized, placebo-controlled clinical trial.
Mehrzad V1, Afshar R1, Akbari M2. Adv Biomed Res. 2016 Mar 22;5:60. doi: 10.4103/2277-9175.179182. eCollection 2016.
BACKGROUND: Cachexia can occur as part of many end-stage or chronic diseases, and chronic obstructive pulmonary disease. This study was aimed to evaluate the effect of Pentoxifylline in patients with cancer cachexia.
3.Can Pentoxifylline be used as Adjunct Therapy to ACE Inhibitors and ARBs in Preserving Kidney Function?
Carson C1, Al-Makki A, Shepler B. J Pharm Pharm Sci. 2016 Jan-Mar;19(1):1-7. doi: 10.18433/J3K020.
PURPOSE: To determine if there is sufficient evidence to recommend the addition of pentoxifylline to standard ACE inhibitor and ARB therapy in chronic kidney disease patients to reduce proteinuria and preserve kidney function.
4.Therapeutic effect of pentoxifylline on reproductive parameters in diabetic male mice.
Feyli SA1, Ghanbari A1, Keshtmand Z2. Andrologia. 2016 May 2. doi: 10.1111/and.12604. [Epub ahead of print]
In this study, we aimed to investigate the effects of pentoxifylline (PTX) on male reproductive parameters in diabetic mice. Male adult mice (n = 24) were divided into control and three experimental groups (n = 6) including Diabetic, Diabetic + PTX and PTX groups. Diabetes was induced by single injection of streptozotocin (60 mg kg-1 ). PTX was administered intraperitoneally at the dose of 12 mg kg-1 for 14 days 1 week after diabetes induction. Serum levels of testosterone and blood glucose were determined and collected spermatozoa from cauda epididymidis analysed. Based on histological slides prepared from testis, the diameter of seminiferous tubules was determined using Motic camera and software and also apoptosis using TUNEL assay. Data were analysed using one-way anova method, and P < 0.05 was considered statistically significant. The mean of seminiferous tubules diameter, final body weight, testis weight, sperm parameters and testosterone hormone level in PTX-treated diabetic group indicated a significant increase compared to diabetic one, whereas apoptosis index and blood glucose were decreased in this comparison (P < 0.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Phosphodiesterase (PDE) Products

CAS 1236858-52-8 PF 04449613

PF 04449613
(CAS: 1236858-52-8)

PF 04449613 is a potent PDE9 inhibitor (IC50 = 22 nM), and also shows a high affinity for cGMP (Km ~170 nM). Some studies suggest that elevating the level of cG...

CAS 947620-48-6 RVT-501

(CAS: 947620-48-6)

RVT-501, also referred to E6005, is a selective phosphodiesterase 4 (PDE4) inhibitor (IC50= 2.8 nM) with potential effect to treat atopic dermatitis.

CAS 794568-92-6 BAY 73-6691

BAY 73-6691
(CAS: 794568-92-6)

BAY 73-6691 is a phosphodiesterase inhibitor selective for the PDE9A subtype under the development of Bayer. It selectively inhibits human PDE9 with IC50 value ...

(CAS: 1642303-38-5)

ITI214 is a highly selective PDE1 inhibitor (Ki = 58 pM) at picomolar concentration without disrupting other PDE family members and a panel of enzymes, receptor...

CAS 171596-29-5 Tadalafil

(CAS: 171596-29-5)

Tadalafil binds to PDE5 with KD of 2.4 nM.

CAS 686770-80-9 BC 11-38

BC 11-38
(CAS: 686770-80-9)

BC 11-38 is a potent and selective phosphodiesterase (PDE) 11 inhibitor (IC50 = 0.28 μM for PDE11; IC50 values are >100 μM for PDE1 - PDE10). BC 11-38 increases...

CP-461 free base
(CAS: 227619-92-3)

CP 461, belonging to a class of novel proapoptotic drugs with antineoplastic effect, specifically inhibit cyclic GMP phosphodiesterases but not cyclooxygenase-1...

CAS 81840-15-5 Vesnarinone

(CAS: 81840-15-5)

Vesnarinone, a quinolinone derivative, is a cardiotonic agent. It has pharmacodynamic effects include inhibition of phosphodiesterase III (PDE3) activity, incre...

Chemical Structure

CAS 6493-05-6 Pentoxifylline

Quick Inquiry

Verification code

Featured Items